Our solutions:

• Hospitals• Sports• Back to work• Corporate
EXPLORE

About us

The COVID-19 MedBot is powered by Akkure, an innovative digital health startup based in Dublin. Akkure’s vision is to put control over health and medical data back into the hands of patients. We have designed a block-chain enabled digital health platform that allows users to own their own genetic information. Akkure’s platform enables users to keep their information private, or, if they choose to do so, be rewarded fiscally for sharing their information anonymously and securely with research organizations.

By joining the Akkure network, you are not only actively facilitating medical breakthroughs, but furthermore, becoming part of an innovative, patient focused, medical community looking to improve public health and revolutionize modern medicine.

Read more about the release of the COVID Medbot.

Local updates

RSSCDC Online Newsroom
RSSBBC News - Health
RSSNews (English) - World Health Organization
  • WHO discontinues hydroxychloroquine and lopinavir/ritonavir treatment arms for COVID-19
    <p dir="ltr"></p> <p dir="ltr">WHO today accepted the recommendation from the Solidarity Trial’s International Steering Committee to discontinue the trial’s hydroxychloroquine and lopinavir/ritonavir arms. The Solidarity Trial was established by WHO to find an effective COVID-19 treatment for hospitalized patients.</p> <p dir="ltr">The International Steering Committee formulated the recommendation in light of the evidence for hydroxychloroquine vs standard-of-care and for lopinavir/ritonavir vs standard-of-care from the Solidarity trial interim results, and from a review of the evidence from all trials presented at the 1-2 July WHO Summit on COVID-19 research and innovation. </p> <p dir="ltr">These interim trial results show that hydroxychloroquine and lopinavir/ritonavir produce little or no reduction in the mortality of hospitalized COVID-19 patients when compared to standard of care. Solidarity trial investigators will interrupt the trials with immediate effect. </p> <p dir="ltr">For each of the drugs, the interim results do not provide solid evidence of increased mortality. There were, however, some associated safety signals in the clinical laboratory findings of the add-on Discovery trial, a participant in the Solidarity trial. These will also be reported in the peer-reviewed publication. </p> <p dir="ltr">This decision applies only to the conduct of the Solidarity trial in hospitalized patients and does not affect the possible evaluation in other studies of hydroxychloroquine or lopinavir/ritonavir in non-hospitalized patients or as pre- or post-exposure prophylaxis for COVID-19. The interim Solidarity results are now being readied for peer-reviewed publication.</p> <div><br></div> <div><br></div>
  • Timeline of WHO’s response to COVID-19
    WHO provides this timeline of the organization’s COVID-19 response activities for general information. WHO will update the timeline on a regular basis and in light of evolving events and new information. Unless noted otherwise, country-specific information and data are as reported to WHO by its Member States. This timeline continues in the spirit of, and supersedes, the WHO Rolling Updates and the WHO Timeline statement published in April 2020. It is not intended to be exhaustive and does not contain details of every event or WHO activity. As of 29 June 2020, the following milestones and events focused on COVID-19 have taken place: • The Director-General and Executive Director of the WHO Health Emergencies Programme have held 74 media briefings. The Director-General's opening remarks, transcripts, videos and audio recordings for these media briefings are available online. • There have been 23 Member State Briefings and information sessions. • EPI-WIN, WHO’s information network for epidemics, has convened 60 technical webinars, making available 287 expert panellists to more than 13,500 participants, from more than 120 countries and territories, with representation from as many as 460 organizations. • The OpenWHO platform has had more than 2.7 million enrolments in its COVID-19 courses. Free training is available on 13 different topics translated into 31 languages to support the coronavirus response, for a total of 100 COVID-19 courses. • WHO’s landscape of COVID-19 candidate vaccines lists 17 candidate vaccines in clinical evaluation and 132 in preclinical evaluation. In addition to the selected guidance included below, all of WHO’s technical guidance on COVID-19 can be found online here. All events listed below are in the Geneva, Switzerland time zone (CET/CEST). Note that the dates listed for documents are based on when they were finalised and timestamped.
RSSIndependent.ie - Health RSS Feed

Symptoms

What can I expect?

Most commonly reported symptoms

Most commonly reported symptoms

The most commonly reported symptoms of the coronavirus are as listed below:

  1. A cough (any kind of cough, not just dry)
  2. Shortness of breath
  3. Breathing difficulties
  4. Fever

 

COVID-19 Public Health Advice

COVID-19 Public Health Advice

For further information on facts about COVID-19, please click the button below.

 

 

 

Experiencing any symptoms?

Experiencing any symptoms?

If you are experiencing any of the symptoms, do not panic.

  1. Self-isolate
  2. Engage in a MedBot consult to ascertain your personal risk assessment
  3. Follow the resulting guidelines for your next steps based on HSE and WHO recommendations. (Source: HSE)

How the COVID Medbot works

Engage in a MedBot consult.
Ascertain your risk assessment based on the results of the MedBot.
Follow the resulting guidelines given by the MedBot based on HSE recommendations.

Myths

Much of the panic surrounding the novel coronavirus outbreak has come from several myths that have been circulating regarding the nature of the virus. We’re here to debunk those myths, and provide you with up to date information from the HSE and WHO.

“Wearing a mask will protect me from the virus”

Standard surgical masks cannot protect you from the new coronavirus, as they are not designed to block out viral particles and often do not lay flush to the face. Using masks is unlikely to be of any benefit if you are not sick. However, there may be a benefit for sick people to use a mask to prevent the spread of infected droplets to other people.

(source: HSE)

“Cold weather and snow can kill the coronavirus”

There is no reason to believe that cold weather can kill the new coronavirus or other diseases, as the normal human body temperature remains around 37ºC regardless of external temperature or weather.

(source: WHO)

“Hand dryers can kill the new coronavirus”

No, hand dryers are not effective in killing COVID-19. To protect yourself against the new coronavirus you should frequently clean your hands with an alcohol-based hand rub, or wash them with soap and water. Once your hands are cleaned, you should dry them thoroughly by using paper towels or a warm air dryer.

(source: WHO)

About AKKURE

The AKKURE team possess a fusion of expertise in the medical, information engineering and healthcare space, with their current focus on the treatment of respiratory illnesses, rare diseases and oncology. Most notably, their founder Dr. Oran Rigby, a professor of robotics and autonomous systems, is also a consultant in intensive care medicine and surgery, whilst holding master’s degrees in disaster medicine, trauma surgery and orthopaedic medicine. Co-founder Dr Amy Hollingworth is a respiratory and lung transplant specialist, with a master’s degree in public health, focusing on pandemic influenza.

Singularity Alpha Limited (trading as Akkure4Covid.com), NovaUCD Innovation Centre, University College Dublin, Dublin 4, Ireland.

Contact us

Please fill in the form below if you have any questions.

Subject